AngioDynamics Delivers Strong Fiscal Year 2026 Performance with 18% Med Tech Growth
AngioDynamics, a leading medical technology company, recently reported its Fiscal Year 2026 fourth quarter and full year earnings call, showcasing impressive growth and profitability. The company's strong performance in the med tech segment, which accounted for 47% of total revenue, demonstrates its successful strategy to transform into a fast-growing and profitable business.
According to Jim Clemmer, AngioDynamics President and Chief Executive Officer, the company achieved full-year med tech growth of more than 18%, solidifying its position in large, fast-growing markets. This growth was driven by the company's platform technologies across cardiovascular and interventional oncology, which took share in these significant markets.
What's more, AngioDynamics' commitment to discipline and innovation paid off, as the company absorbed tariffs that were not previously in its business while still increasing profitability. Clemmer emphasized that this achievement was the result of years of hard work by the team, demonstrating their dedication to delivering high-quality products and services for patients.
One notable example of the company's success is Auryon, which delivered its 20th consecutive quarter of double-digit year-over-year growth. The product continues to win market share across all sites of care, solidifying its position as a strong performer in AngioDynamics' portfolio.
The company's President and CEO expressed pride in the team's performance, stating that Fiscal Year 2026 was another year of proof that the strategy is working and playing out as planned. With a full year now behind them, AngioDynamics is poised to continue its growth trajectory into Fiscal Year 2027.
As reported by Executive Vice President and Chief Financial Officer Steve Trowbridge during the earnings call, the company's financial results demonstrate sustained profitability alongside impressive revenue growth. The presentation will provide further insight into the company's operating results and financial performance during this morning's conference call.
The strong fiscal year 2026 performance demonstrates AngioDynamics' commitment to delivering innovative medical technology solutions that meet the evolving needs of patients and healthcare providers. With its successful strategy in place, the company is well-positioned for continued growth and success in Fiscal Year 2027 and beyond.
